CCND1 and endometrioid adenocarcinoma: Such conclusions are further strengthened by reports assessing the ability of 5-aza to decrease β-catenin and cyclin D1 expression in endometrioid carcinoma and prostate cancer cells (Zhang et al., 2014; Liao et al., 2020).